Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982982 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Delta-9-THC and Iomazenil in Healthy Humans
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT00982982 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 17 participants.
The verdict
NCT00982982, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.
Interventions
- DRUG THC and Iomazenil
- DRUG Placebo (control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-02-11 |
| Est. Completion | 2013-02-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982982
The ClinicalTrials.gov registry entry for NCT00982982 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which THC and Iomazenil is the first listed.
NCT00982982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00982982 about?
NCT00982982 is a clinical study titled "Effects of Delta-9-THC and Iomazenil in Healthy Humans". The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that...
What is the current status of trial NCT00982982?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2009-02-11. Estimated completion is 2013-02-22.
What interventions are being tested in trial NCT00982982?
The interventions under investigation include: THC and Iomazenil (DRUG), Placebo (control) (DRUG).
Who is sponsoring clinical trial NCT00982982?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.